A032103, MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
A032103 will explore two novel concepts, seeking to simultaneously escalate adjuvant treatment in patients at highest risk and de-escalate adjuvant treatment in patients at lowest risk, within the context of an integrated phase 2/3 and phase 3 clinical trial.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855695
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
